Tiaa Fsb boosted its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 4.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 67,206 shares of the company’s stock after buying an additional 2,794 shares during the quarter. Tiaa Fsb’s holdings in Eli Lilly And Co were worth $7,212,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Integrated Wealth Concepts LLC acquired a new position in shares of Eli Lilly And Co in the second quarter valued at about $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of Eli Lilly And Co in the second quarter valued at about $114,000. Legacy Advisors LLC increased its holdings in shares of Eli Lilly And Co by 118.0% in the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock valued at $116,000 after purchasing an additional 733 shares during the period. Fort L.P. acquired a new position in shares of Eli Lilly And Co in the second quarter valued at about $121,000. Finally, Financial Management Professionals Inc. acquired a new position in shares of Eli Lilly And Co in the second quarter valued at about $128,000. 76.38% of the stock is currently owned by institutional investors.
In other news, SVP Alfonso G. Zulueta sold 7,000 shares of the company’s stock in a transaction dated Thursday, October 4th. The stock was sold at an average price of $114.64, for a total value of $802,480.00. Following the sale, the senior vice president now owns 45,224 shares in the company, valued at $5,184,479.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 185,000 shares of the company’s stock in a transaction dated Tuesday, July 24th. The stock was sold at an average price of $92.03, for a total value of $17,025,550.00. Following the completion of the sale, the insider now owns 121,631,601 shares in the company, valued at approximately $11,193,756,240.03. The disclosure for this sale can be found here. Insiders sold 1,960,271 shares of company stock worth $199,950,452 in the last 90 days. Company insiders own 0.11% of the company’s stock.
Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, July 24th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The firm had revenue of $6.36 billion for the quarter, compared to the consensus estimate of $6.05 billion. During the same quarter in the prior year, the business earned $1.11 earnings per share. The company’s revenue was up 9.1% compared to the same quarter last year. On average, research analysts predict that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be paid a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.01%. Eli Lilly And Co’s payout ratio is 52.57%.
A number of research analysts have recently weighed in on the company. Guggenheim assumed coverage on Eli Lilly And Co in a report on Monday, October 8th. They issued a “buy” rating on the stock. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $129.00 price objective on the stock in a report on Tuesday, October 9th. ValuEngine raised Eli Lilly And Co from a “hold” rating to a “buy” rating in a report on Monday, October 8th. BMO Capital Markets raised Eli Lilly And Co from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $107.00 to $130.00 in a report on Thursday, October 4th. Finally, JPMorgan Chase & Co. set a $123.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Friday, October 5th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $109.80.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Using the New Google Finance Tool
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.